338 research outputs found

    On Being Special

    Get PDF

    The Living Jesus Among His Churches: Revelation 1-3

    Get PDF

    Use of positive selection methods for discovery and improvement of nitroreductase enzymes for cancer gene therapy

    Get PDF
    Bacterial nitroreductases are members of a diverse family of oxidoreductase enzymes that are capable of activating nitroaromatic compounds, including anticancer prodrugs such as CB 1954 and PR-104A. This capability is useful in the anti-cancer gene therapy strategy known as gene-directed enzyme prodrug therapy (GDEPT), which involves the killing of tumour cells through activation of an inert prodrug to its cytotoxic form, following selective delivery of a genetically encoded prodrug-converting enzyme to cancerous tissues. A key limitation in nitroreductase-based GDEPT has been the inability to rapidly and non-invasively determine vector localisation and gene delivery prior to systemic administration of prodrug. To address this we have developed dual-purpose nitroreductases that exhibit the ability to efficiently activate both GDEPT prodrugs and next-generation radioisotope-labelled PET imaging probes, in a manner that renders the probes temporarily cell-entrapped for detection using a PET scanner. This capability places greater control of the therapy in the hands of the clinician, and will facilitate clinical development of this treatment. One key focus has been the engineering of more efficient enzymes using both random and targeted mutagenesis strategies. A complementary strategy has been the discovery of novel nitroreductases through the screening of metagenomic fragments of DNA from the unculturable bacteria present in New Zealand soil. To enable efficient screening of these libraries, we have developed an array of genetic and biochemical tools for the rapid selection of active nitroreductases. Here we have investigated the effectiveness of these different approaches for improving nitroreductase activity, and demonstrate their utility in improving activity with specific target substrates including next- generation prodrugs and PET imaging probes

    Simultaneous randomisation of eight key active site residues in E. coli NfsA to generate superior nitroreductases for prodrug activation

    Get PDF
    There is a substantial gap between the levels of enzyme activity Nature can evolve and those that scientists can engineer in the lab. This suggests that conventional directed evolution techniques involving incremental improvements in enzyme activity may frequently fail to ascend even local fitness maxima. This is most likely due to an inability of step-wise evolutionary approaches to effectively retain mutations that are beneficial in combination with one another, but on an individual basis are neutral or even slightly deleterious (i.e., exhibit positive epistasis). To overcome this limitation, we are seeking to “jump” straight to an enzyme with peak activity by conducting simultaneous mass randomisation of eight key active site residues in Escherichia coli NfsA, a nitroreductase enzyme that has several diverse applications in biotechnology. Using degenerate codons, we generated a diverse library containing 425 million unique variants. We then applied a powerful selection system using either or both of two recently identified positive selection compounds, which has enabled us to recover a diverse range of highly active nitroreductase variants. These have been screened against a panel of prodrug substrates to identify variants that are improved with specific prodrug substrates of interest. A primary focus has been developing nitroreductases as tools for targeted cell ablation in zebrafish. The basic system involves co-expression of a nitroreductase and fluorescent reporter under the control of a cell type specific promoter in a transgenic fish. Expression of the nitroreductase selectively sensitises target cells to a prodrug which, following nitroreduction, yields a cytotoxic compound that causes precise targeted cell ablation. We have identified several nil-bystander prodrugs that are able to selectively ablate nitroreductase expressing cells with no harm to nearby cells, and have paired these with highly specialised NfsA variants to improve the efficacy and accuracy of cell ablation. We have also screened our mass-randomisation libraries to recover nitroreductases that have non-overlapping prodrug specificities, to be used in a multiplex cell ablation system. This expands upon the previous system, by using pairs of selective nitroreductases and two different prodrugs to facilitate independent ablation of multiple cell types. For example, we have identified a specialist NfsA variant that has activity for tinidazole and not for metronidazole, achieved by including metronidazole as a simultaneous counter-selection during the initial positive selection process. This elegant positive/negative selection eliminated activity with metronidazole, while still ensuring that some level of nitroreductase activity was retained overall

    Assessing the Impact of Stakeholder Engagement in Management Strategy Evaluation

    Get PDF
    After completing a large, regional, multi-use Management Strategy Evaluation, we attempt to assess the impact of stakeholder engagement on the project. We do so by comparing the original project plan to the actual project development and highlight the changes which can be more directly related to stakeholder engagement aided by the application of a logic model for program evaluation. The impact can be summarised into four broad classes: a) change in the actual project development; b) a measurable change in the network of interactions both stakeholders (which includes researchers); c) changes in how the computer model was developed and run; and d) changes in attitudes among stakeholders (including researchers). We discuss these changes, the way they have been detected and some lessons we learnt which may benefit future Management Strategy Evaluation projects
    corecore